secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyra Therapeutics, Inc. (LYRA)
CIK:        0001327273
Form:       8-K
Filed at:   2021-09-15T23:59:59+00:00
Accession:  0001564590-21-048046
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Lyra Therapeutics appoints Jason Cavalier as CFO; R. Don Elsey to transition out
--------------------------------------------------------------------------------

- Jason Cavalier appointed CFO, Treasurer, Secretary, principal financial and accounting officer effective Sept 12, 2021.
- Cavalier receives $400K base salary, 40% target bonus, and option for 104,000 shares vesting over 4 years.
- Outgoing CFO R. Don Elsey will work full-time through Oct 6, then part-time until Dec 31, 2021 under a transition agreement.
- Elsey retains $375K base salary (prorated during part-time) and eligible for 2021 bonus up to 40% of actual salary earned.
- Cavalier also receives up to $6,250/month for travel between New York and Watertown, plus corporate apartment and tax gross-up.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1327273/000156459021048046/0001564590-21-048046-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1327273/000156459021048046/lyra-8k_20210912.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-048046

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer